The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

A New Jersey pharmaceutical company filed a lawsuit in federal court last week challenging a new Maine law aimed to protect a ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Both companies have attractive dividend programs that should please income-focused investors. We've seen several investing ...

When ideology overtakes pragmatism in crafting public policies, it portends danger to society. The recent decision by the ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are ...

ArteraAI Prostate forecasts potential long-term outcomes of a patient's prostate cancer biopsy slide based on digital pathology images.